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 Development of a New In Vivo Optical Probe 
for Biological Diagnosis and Therapy 
 Michitaka  Ozaki ,  Takeaki  Ozawa , and  Yuma  Yamada 
 Abstract  Real-time imaging of the speciﬁ c markers of lesions in the living body 
will provide valuable information in various physiopathological situations. 
Clinically, real-time imaging will deﬁ nitely aid accurate diagnosis and rational 
 therapy, especially in the surgical ﬁ eld. 
 In this chapter, we describe some unique optical probes for “biological imaging” 
and our recent challenge in undertaking development of a new type of in vivo probe. 
The reduction-oxidation-sensitive green ﬂ uorescent protein (roGFP) and biolumi-
nescent luciferase probe for caspase-3 activity have been useful for understanding 
of the dynamic changes of liver redox states and apoptotic cell death. To overcome 
the difﬁ culty of imaging in deeper lesions by optical probes, we newly developed a 
far-red bioluminescent probe. Lastly, we have undertaken the challenge to develop 
an innovative optical probe that switches “on” only when the probe recognizes a 
target molecule to reduce non-speciﬁ c signals in vivo. The project of developing 
this unique probe is still underway. 
 Regarding a carrying system of the probe into cells in vivo, we have developed a 
liposome with cell-penetrating octa-arginine peptides (R8) and a pH-sensitive fuso-
genic peptide (GALA), which delivers the functional proteins into cells efﬁ ciently 
and rapidly in vivo. 
 We believe that these optical probes will provide a new avenue toward new 
 diagnosis and therapy to come in the future. 
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 Abbreviations 
 Ad pcFluc  Adenovirus vector encoding  pcFluc-DEVD 
 Dlk1  Human Delta-like protein 
 AP-1  Activator protein 1 
 ATP  Adenosine triphosphate 
 BG  Benzylguanine 
 BRET  Bioluminescence resonance energy transfer 
 CLuc  Cypridina luciferase 
 DEVD  Asp-Glu-Val-Asp (a substrate sequence of caspase-3) 
 FBP  Far-red bioluminescent protein 
 FLuc  Fireﬂ y luciferase 
 FlucC-SNAP  C-terminal fragment of luciferase conjugated with SNAP 
 FlucN-SNAP  N-terminal fragment of luciferase conjugated with SNAP 
 H/R  Hypoxia and reoxygenation 
 I/R  Ischemia and reperfusion 
 MAPK  Mitogen-activated Protein Kinase 
 MEND  Multi-functional envelope-type nano device 
 NF-kB  Nuclear factor-kappa B 
 OS  Oxidative stress 
 pc Fluc-DEVD  Cyclic luciferase reﬂ ecting caspase-3 activity 
 PET  Positron emission tomography 
 roGFP  Reduction-oxidation sensitive green ﬂ uorescent protein 
 ROS  Reactive oxygen species 
 R8  Octa-arginine peptide 
 SNAP  A 182 residues polypeptide that can be fused to any protein of 
interest 
 Introduction 
 Real-time monitoring of molecular markers of lesions in the living body will  provide 
valuable information on various physiopathological phenomena. This will aid 
understanding of lesions qualitatively as well as quantitatively. Clinically, this will 
lead to more accurate diagnosis and rational therapy. Especially in the surgical ﬁ eld, 
this kind of technology will enable us to “see” the biological characteristics (and 
potential pathological/progressive behavior) of the lesions during operation as well 
as its location, size, and expansion, which will deﬁ nitely help the surgeon select the 
best surgical procedure for the patient. 
 The conventional imaging technologies commonly used in clinical practice 
include CT, PET-CT, and MRI. These technologies provide useful and geographical 
information about the location, size, shape, and expansion (including distant metas-
tasis), and aid accurate clinical diagnosis and pre-operative staging. However, they 
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do not show the biological characteristics of the lesion, nor its exact location during 
the operation. In addition, they require a lot of space and much expense for 
installation. 
 On the other hand, optical imaging by ﬂ uorescence or bioluminescence will pro-
vide biological information with sophisticated probes at low cost and in a small 
space. Disadvantages of optical imaging are that it requires a customized probe 
(ﬂ uorescence or bioluminescence) and has difﬁ culty in imaging deeper lesions. In 
addition, signals from optical probes are relative, not absolute (Table  1 ).
 An Optical Probe for In Vivo Imaging of Caspase-3 Activity 
 Many optical probes have been developed to visualize protease activities for 
 biological in vivo imaging [ 1 – 7 ]. They have been used to analyze the dynamic 
changes in the cell and organ stresses and injuries, including hypoxia and reoxygen-
ation (H/R) and ischemia and reperfusion (I/R) of cells and organs, respectively. 
I/R- induced injury is an important concern in various clinical situations, including 
surgical resection of organs, transplantation of organs and cells, and myocardial/
cerebral/intestinal infarction. In these clinical situations, prolonged ischemia 
 followed by reperfusion results in extended organ injury caused by apoptosis, 
necrosis, and organ failure [ 8 ]. Although the mechanisms of I/R-induced injury are 
complex, post-ischemic apoptotic and/or necrotic injury play a pivotal role in sub-
sequent organ failure [ 9 ,  10 ]. Therefore, noninvasive monitoring of cell and organ 
injury (e.g., caspase activity) in vivo is deﬁ nitely beneﬁ cial and is able to provide 
important clues for treatment. 
 We previously developed a novel probe of cyclic luciferase reﬂ ecting caspase-3 
activity (pc Fluc-DEVD ) [ 2 ]. Two fragments of DnaE inteins are fused with neigh-
boring N-terminal and C-terminal ends of ﬁ reﬂ y luciferase, which are connected 
 Table 1  Comparison between conventional imaging technology and optical imaging 





 (1) Can image exact size of lesions 
macroscopically 
 (1) Does not provide information 
on biological features of lesions 
 (2) Can image whole body  (2) Does not show exact locations 
during operation 
 (3) Enables preoperative diagnosis 
and clinical staging 
 (3) High cost and space 
occupying 
 Optical imaging 
(ﬂ uorescence/
bioluminescence) 
 (1) Can image molecules/cells of 
interest; enables biological imaging 
of lesions 
 (1) Not good at examining deep 
lesions 
 (2) Low cost and space saving; 
enables intra- operative real-time 
imaging 
 (2) Needs ﬂ uorescent/
bioluminescent reagents for 
imaging 
 (3) Relative estimation 
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with DEVD (Asp–Glu–Val–Asp [a substrate sequence of caspase-3]). After transla-
tion into a single polypeptide, the N-terminal and C-terminal ends of the luciferase 
are ligated by protein splicing, producing a closed circular polypeptide chain. The 
cyclic luciferase structure is distorted and therefore almost loses its bioluminescent 
activity. When caspase-3 is activated in cells, the DEVD chain is cleaved, which 
restores ﬁ reﬂ y luciferase (Fluc) luminescent activity by returning to the original 
structure (Fig.  1 ) [ 11 ].
 This cyclic luciferase was ﬁ rst applied for quantitative measurement of caspase-3 
activity in living cells. HeLa cells transfected with this probe were stimulated with 
staurosporine, an inducer of apoptosis. This bioluminescent probe based on cyclic 
luciferase allowed precise and quantitative measurements of caspase-3 activity in 
living cells. Moreover, the response of this cyclic luciferase to caspase-3 activation 
was rapid and paralleled biochemically assessed apoptosis. 
 This imaging technology by cyclic luciferase could be applied for in vivo real- 
time imaging of caspase-3 activity in living mice. We successfully imaged the cas-
pase- 3 activity in post-ischemic liver using our caspase-3 probe (Fig.  2 ). By 
transfecting the adenovirus vector encoding  pcFluc-DEVD (Ad pcFluc ), we investi-
gated whether or not this probe could monitor caspase-3 dependent apoptosis in the 
mouse liver during I/R (Fig.  2 ) [ 11 ]. We conﬁ rmed the efﬁ cacy of the probe in 









Luciferase inactive Luciferase active
Luciferase
(open)
bioluminescent probe for Caspase-3 activity
-distorted circular luciferase senses caspase-3 activity -
 Fig. 1  Bioluminescent probe for caspase-3 activity. The principle for monitoring activity of cas-
pase- 3 is based on cyclic ﬁ reﬂ y luciferase (Modiﬁ ed from Ozaki et al. [ 11 ], with permission) 
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 An Optical Probe for In Vivo Imaging of the Hepatic 
Redox State 
 Reactive oxygen species (ROS) generated during I/R of organs certainly play a 
pivotal role in I/R-induced organ injury and failure [ 12 ]. Hepatic I/R results in mas-
sive cell death (a) through apoptosis and necrosis mediated by excessive generation 
of ROS in hepatocytes early after I/R [ 13 ]; and (b) through necrosis caused by neu-
trophilic inﬁ ltration in the later phase [ 14 ]. According to the numerous studies on 
liver I/R in mice, organ injury in the early post-I/R period is deﬁ nitely mediated by 
generation of ROS in hepatocytes [ 15 ,  16 ]. Excessive ROS directly exert deleterious 
effects on cells and tissues through lipid peroxidation, protein degradation, and 
DNA damage. In addition, redox-sensitive molecules, such as nuclear factor- kappa 
B (NF-κB), activator protein 1 (AP-1), and some mitogen-activated protein kinases 
(MAPKs), are potentially activated under these oxidative conditions and play 
 pivotal roles in I/R-induced injury [ 17 ]. Therefore, monitoring cellular redox states 
by visualizing cellular ROS in post-I/R tissue has been one of the possible strategies 
for forecasting I/R-induced injury and failure [ 18 ]. These considerations suggest 
that the post-I/R redox state may be a good prognostic indicator of liver injury and 
function after liver surgery and transplantation, implying that in vivo monitoring 
may provide more diagnostic and therapeutic options in clinical liver surgery and 
transplantation. 
 For in vivo assays of tissue oxidative stress (OS), tissues are usually  homogenized 
and subsequently assayed, either with redox-sensing electrodes or by measuring the 
ratios of the reduced and oxidized forms of glutathione and ascorbate. Recently, the 
redox states of tissues have also become assessable by using the dyes 5- (and 6-) 
















In vivo imaging of caspase-3 activity by the optic probe 
 Fig. 2  In vivo imaging of caspase-3 activity by the optical probe. An ischemic insult to the liver 
induced caspase-3 activation (Modiﬁ ed from Ozaki et al. [ 11 ], with permission) 
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tate [ 20 ]. Although such approaches allow evaluation of the sum of the oxidized and 
reduced species present, and thereby estimation of the overall redox state of the 
tissue, these techniques do not allow measurement of redox potentials in real time. 
More importantly, homogenization of tissues precludes the possibility of monitor-
ing dynamic changes in OS in the same animal and organ. 
 A newly developed reduction-oxidation-sensitive green ﬂ uorescent protein 
(roGFP) probe (GFP with mutations of C48S, S147C, Q204C, and S65T) [ 1 ] could 
be applied for in vivo imaging. Use of the roGFP probe enables evaluation of cell 
and organ redox states non-invasively and continuously. Adenovirally transduced 
roGFP in the mouse liver was shown to act as a good indicator of pre- and post- 
ischemic liver redox states (Fig.  3 ) [ 10 ]. Through use of this roGFP probe, post- 
operative liver injury may be predicted by real-time monitoring of liver redox states.
 Optical Imaging of Deeper Lesions in the Living Body 
 An increasing number of antibodies have been applied for targeting antigens on the 
surface of cancer cells for clinical diagnosis and therapy, on the basis of the fact that 
some speciﬁ c antigens expressed on the cancer cell surface reﬂ ect malignant 
 behaviors including invasion, metastasis, and neo-vascularization [ 21 – 23 ]. Real-
time visualization of tumor-speciﬁ c antigens in the living body will enable timely 
understanding of cancer expansion and its biological behaviors, and prediction of 
the patient’s prognosis in the near future. 

























































 Fig. 3  In vivo imaging of I/R-induced oxidative stress of the mouse liver. The roGFP probe 
showed dynamic changes in liver redox states. The  left panel depicts representative images of the 
dynamic changes after 60 min of ischemia, followed by reperfusion (oxidation,  green to blue ; 
reduction,  orange to red ) (Modiﬁ ed from Haga et al. [ 10 ], with permission) 
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 Fluorescence and bioluminescence imaging technologies have played important 
roles in molecular imaging in cells and small animals [ 24 – 26 ]. Photon detection is 
easy to use, cost saving, and space saving, compared with radioisotope imaging. 
Basically, bioluminescence imaging is achieved with a luciferin–luciferase reaction 
in the presence of sufﬁ cient amounts of molecular oxygen and adenosine triphos-
phate (ATP). However, most bioluminescence spectra are observed in the visible 
region, which overlaps with the absorption spectra of hemoglobin and tissue con-
stituents, therefore attenuating the bioluminescence intensity in living animals. 
 Recently, a self-illuminating quantum dot probe was developed to improve the 
light penetration based on bioluminescence resonance energy transfer (BRET) 
between the bioluminescence of  Renilla luciferase and quantum dots [ 27 ]. The mul-
tivalent conjugation of  Renilla luciferase to single dots allowed for highly efﬁ cient 
BRET between luciferase and quantum dots. However, the large size of the conju-
gate caused problems in metabolism and localization in vivo [ 28 ]. Several far-red 
ﬂ uorescent protein variants showing maximal emission at around 650 nm have been 
developed for in vivo imaging [ 29 ], but are not well characterized as energy 
 acceptors for BRET systems. On the other hand, the organic dye indocyanine and its 
derivatives have molecular weights of less than 1,200 Da; they produce far-red 
 ﬂ uorescence and have been widely used for in vivo imaging [ 30 ]. 
 Luciferase conjugated to such organic dyes is expected to create new possibili-
ties for in vivo application.  Cypridina luciferase (CLuc) catalyzes the oxidation of 
 Cypridina luciferin to yield light emission peaking at 460 nm [ 31 ]. 
 The luciferase genes from both  Cypridina hilgendorfi i and  C. noctiluca have 
been cloned [ 32 ], the latter of which we used. This self-secretory CLuc of 62 kDa 
has some unique properties as a bioluminescent enzyme [ 33 ]. The secreted protein 
contains 17 disulﬁ de bond pairs and is highly stable under physiological conditions. 
Its turnover rate (1400 luciferin molecules per minute) is the highest among known 
luciferases [ 34 ]. We have expressed recombinant CLuc in yeast and applied it to 
ELISA. We conjugated a far-red ﬂ uorescent indocyanine derivative to biotinylated 
CLuc via glycol chains and named this far-red bioluminescent protein (FBP). 
 A monoclonal antibody against human Delta-like protein (anti-Dlk1), one of the 
embryonic antigens expressed on the surface of many cancer cells, including hepa-
tocellular carcinoma, was then produced. Using anti-Dlk1 monoclonal antibody 
linked to FBP via biotin–avidin interaction, we achieved bioluminescence imaging 
of cancer cells in vivo in mice (Fig.  4 ).
 However, very unfortunately, there were some non-speciﬁ c signals from the tis-
sues that did not express Dlk-1, though the tumor implanted into the liver itself was 
imaged clearly by this probe. This may have been because excessive and unbound 
antibodies circulating in the blood or captured in tissues emitted signals when the 
substrate was injected. In order to apply this probe to clinical application, non- 
speciﬁ c signals must be reduced as much as possible. So, we have launched the 
following new project. 
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 Development of an In Vivo Optical Probe for Antigen-Specifi c 
Imaging Inside/Outside Cells 
 For accurate biological diagnosis and rational therapy in clinical practice, we need 
to know the biological features of the lesion as well as its size, shape, and extent. 
For this purpose, we plan to develop a new optical probe, which will image the 
 target molecules only after binding to the antigen. This does not allow unbound 
antibody to emit light signals, and therefore it will lead to the reduction of non-
speciﬁ c signals in vivo. Additionally, the probe should be applied to targets inside 
as well as outside cells in vivo, because there are lots of diagnostic and therapeutic 
targets inside as well as outside cells. In order to create a new type of in vivo optical 
probe, the following two technologies have to be developed (Fig.  5 ).
 (A)  Development of an Optical Probe Activated Only When it Binds to the Target 
Molecule 
 In order to develop a probe activated after binding to the target antigen in vivo, 
we have designed a new type of luciferase–antibody conjugated probe. We planned 
to prepare split ﬁ reﬂ y luciferases, the N-terminal and C-terminal fragments of lucif-
erase conjugated with SNAP (a 182-residue polypeptide that can be fused to any 
liver tumor
Image was obtained 24 hr after Luciferin adm (iv)
(400mg/200ml i.v.)
Non-UV irradiated /Luciferin-induced image
tumor
liver tumor
In vivo  imaging by a new optic probe for deeper lesions in mouse
tumor
 Fig. 4  In vivo imaging by a new optical probe for deeper lesions in the mouse. A liver tumor of 
the mouse was imaged, but some non-speciﬁ c signals were observed, probably because of exces-
sive and unbound antibodies 
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protein of interest)—FlucN-SNAP and FlucC-SNAP, respectively—and to prepare 
a polyclonal antibody covalently connected with benzylguanine (Ab-BG). When 
the antibodies with FlucN and FlucC recognize and bind to the close epitopes of the 
same antigen, split luciferase fragments will be reconstituted and activated (Fig.  6 ). 
Theoretically, the probe should enable us to see the target molecule in tissues and 
cells only when it exists.
 We plan ﬁ rst to express FlucN-SNAP and FlucC-SNAP proteins by  Escherichia 
coli , and then to bind benzylguanine (BG) with polyclonal Ab. Lastly, we will con-
jugate these proteins (Fig.  7 ).
 To date, we have succeeded in obtaining sufﬁ cient amounts of FlucN-SNAP and 
FlucC-SNAP proteins by the  E. coli expression system, and we have conﬁ rmed the 
good binding capacity of FlucN-SNAP and FlucC-SNAP proteins to BG. So, we 
have bound BG with polyclonal Ab, and performed conjugation with Fluc-SNAPs. 
We are now examining the probe function in our in vitro system.
 (B)  Development of a Safe and Stable System for Delivery of Optical Probes into 
Cells 
 In order to develop a new system to deliver sufﬁ cient amounts of optical probe safely 
into cells in vivo, we are now developing a new liposome-based delivery system. 
 There seem to be two important processes for developing an effective and rapid 
delivery system (Fig.  8 ). First, the carrier including probes in it should be 
 Fig. 5  Strategy for antigen-speciﬁ c imaging in vivo 
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 Fig. 6  Concept for an antigen-dependent optical probe. When the probes with C-/N-terminal 
 fragments of luciferase recognize the antigen, luciferase is reconstructed and activated 
 Fig. 7  Procedure for making a probe: (1) expression of FlucN-SNAP and FlucC-SNAP; (2) bind-
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 incorporated into cells sufﬁ ciently and rapidly. Second, the incorporated probe 
should be released from the lysosome into the cytosol. These processes should not 
be harmful to the cells and the probes.
 We have already made a prototype liposome-based carrier for efﬁ cient drug 
delivery in vivo. We further added a cell-permeable octa-arginine peptide (R8) to 
the liposome, expecting better incorporation into cells (Fig.  9 ). In the in vitro exper-
iments, the R8 liposome successfully delivered the “antibody” into the cells much 
better than the liposome without R8. The R8 liposome, however, failed to escape the 
“antibody” from the endosome into the cytosol.
 Next, we applied GALA to make the probe release rapidly and efﬁ ciently from 
the endosome into the cytosol (Fig.  10 ). GALA is a 30-amino-acid peptide with a 
glutamic acid–alanine–leucine–alanine repeat that contains a histidine and tryptophan 
residue. GALA changes its conformation from a random coil to an amphipathic 
alpha-helix when pH values are between 7.0 and 5.0. At neutral pH, GALA is water 
soluble, while at acidic pH, GALA binds to bilayer membranes. So it is expected to 
promote rapid fusion of the liposome with the endosomal membrane in the cell. The 
fusogenic liposome was modiﬁ ed with a cell-penetrating R8 and also GALA.
 Fig. 8  Two important processes for efﬁ cient cellular delivery of probes: (1) incorporation into 
cells by endocytosis (a liposome–cell interaction); (2) escape from the endosome into the cytosol 
(a liposome–endosome interaction) 
 
An In Vivo Optical Probe For Biological Imaging
276
Kogure et al. [35, 36]
Nakamura et al. [37]
 Fig. 9  Concept of a multifunctional envelope-type nano device ( MEND ). Octa-arginine (R8) is 
bound to the liposome surface (R8 liposome) 
 Fig. 10  The GALA pH-sensitive fusogenic peptide changes its conformation depending on pH 
values and is expected to promote lipid-membrane fusion 
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 The presence of R8 enhanced the cellular uptake of antibodies, while the 
 mounting of GALA reduced the endosomal entrapment, resulting in release of the 
antibody into the cytosol within 30 min in in vitro experiments. Moreover, com-
pared with the commercially available reagents for protein delivery, the R8/GALA- 
modiﬁ ed liposome was superior in terms of both cellular uptake and transport into 
the cytosol. The speciﬁ c antibody delivered by the R8/GALA liposome was detected 
by its epitope, which indicated that the R8/GALA liposome basically did not dete-
riorate the protein function. 
 Conclusion 
 In this chapter, we have described possible application of an optical probe for “bio-
logical imaging” and our recent challenge in undertaking development of a new 
type of in vivo probe. 
 In the mouse liver I/R model, the ﬂ uorescent probe, roGFP, and bioluminescent 
luciferase probe, pc Fluc-DEVD, were useful in understanding the dynamic changes 
of liver redox states and apoptotic cell death. We could understand the pathological 
signiﬁ cance of OS and apoptosis in I/R-induced liver injury. Because of the  difﬁ culty 
of imaging of deeper lesions by optical probes, we developed a unique probe loaded 
on an antibody. This probe successfully imaged a target molecule in deeper regions 
in mice, but also revealed another problem—an in vivo non-speciﬁ c signal from 
excessive and unbound antibodies. Lastly, we undertook the challenge to develop an 
innovative optical probe which switches “on” only when the probe recognizes a 
target molecule. The project of developing this unique probe is still underway but 
seems very promising at this time. 
 Regarding a carrying system of the probe to target molecules in vivo, we developed 
a liposome bound with a cell-penetrating R8 and GALA. The R8/GALA liposome 
delivered the “antibody” to the cells and also the cytosol efﬁ ciently and rapidly in vivo. 
 In the future, we plan to prove the efﬁ cacy of the new probe carried by the R8/
GALA liposome in in vivo experiments. 
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited.
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